1.88
Schlusskurs vom Vortag:
$1.97
Offen:
$1.97
24-Stunden-Volumen:
5.52M
Relative Volume:
0.70
Marktkapitalisierung:
$648.89M
Einnahmen:
$22,000
Nettoeinkommen (Verlust:
$-173.76M
KGV:
-2.4476
EPS:
-0.7681
Netto-Cashflow:
$-109.53M
1W Leistung:
+8.05%
1M Leistung:
-9.62%
6M Leistung:
+2.17%
1J Leistung:
+52.85%
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ALLO
Allogene Therapeutics Inc
|
1.88 | 604.02M | 22,000 | -173.76M | -109.53M | -0.7681 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-04-10 | Fortgesetzt | Jefferies | Buy |
| 2026-01-09 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Allogene Therapeutics Inc (ALLO) Cash Flow - TradingKey
ALLO|Allogene Therapeutics Inc|Price:1.740|Chg%:-0.080 - TradingKey
Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allogene Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLO - TradingView
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Are Bullish on Top Healthcare Stocks: Tenax Therapeutics (TENX), Allogene Therapeutics (ALLO) - The Globe and Mail
Allogene reports 31% response rate in renal cancer trial By Investing.com - Investing.com South Africa
Allogene Therapeutics (ALLO) Unveils Promising Phase 1 Study Res - GuruFocus
Allogene reports 31% response rate in renal cancer trial - Investing.com
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors - The Manila Times
Allogene Therapeutics Announces Journal of Clinical - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Allogene Therapeutics (ALLO) Q3 2024 earnings summary - Quartr
Allogene Therapeutics (ALLO) Proxy filing Summary - Quartr
Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN
Cancer cell therapy pioneer Allogene’s new CEO is talking about a new revolution - The Business Journals
Form 4 Allogene Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada
Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs - Stock Titan
Allogene Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Roberts Zachary - Moomoo
Allogene Therapeutics shows promise with ALPHA3 trial and ALLO-329, cutting losses and extending cash runway. - Pluang
Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO) - Seeking Alpha
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.com - Investing.com Nigeria
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Yahoo Finance
Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Price to book forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO) - TradingView
Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN
ALLO Forecast — Price Target — Prediction for 2027 - TradingView
Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations - Traders Union
Allogene Therapeutics (ALLO) Edges Higher Near Key Resistance LevelInsider Selling Alerts - dars.gov.et
Recent pharma exec shake-ups signal strategic shifts - Pharma Voice
Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Allogene (ALLO) director Kazam converts 47,700 RSUs and receives 95,400-unit equity grant - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs - Stock Titan
Allogene Therapeutics (ALLO) director receives 144,400 stock options grant - Stock Titan
Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award - Stock Titan
Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery - Stock Titan
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery - Stock Titan
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Allogene Therapeutics Inc-Aktie (ALLO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Yoshiyama Annie | SVP, Finance |
Apr 21 '26 |
Sale |
2.31 |
9,586 |
22,144 |
124,517 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):